{"id":"NCT01546623","sponsor":"Takeda","briefTitle":"A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy","officialTitle":"A Phase 3, Multi-center, Randomized, Open-label, Parallel-group, Comparative Study of TAP-144-SR (3M) to Evaluate Hormone Dynamics, Pharmacokinetics, Safety and Efficacy of TAP-144-SR (6M) 22.5 mg Subcutaneous Injection for 48 Weeks in Prostate Cancer Patients Previously Treated With Hormonal Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-03","primaryCompletion":"2014-04","completion":"2014-04","firstPosted":"2012-03-07","resultsPosted":"2015-07-21","lastUpdate":"2015-07-21"},"enrollment":160,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Prostate Cancer"],"interventions":[{"type":"DRUG","name":"TAP-144-SR(6M)","otherNames":[]},{"type":"DRUG","name":"TAP-144-SR(3M)","otherNames":[]}],"arms":[{"label":"TAP-144-SR(6M)","type":"EXPERIMENTAL"},{"label":"TAP-144-SR(3M)","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate hormone dynamics, pharmacokinetics, safety, and efficacy of TAP-144-SR(6M) against TAP-144-SR(3M) in prostate cancer patients previously treated with hormonal therapy.","primaryOutcome":{"measure":"The Rate of Suppression of Serum Testosterone to Castrate Level","timeFrame":"From the start of study drug administration through Week 48","effectByArm":[{"arm":"TAP-144-SR(6M)","deltaMin":81,"sd":null},{"arm":"TAP-144-SR(3M)","deltaMin":78,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":16,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":81},"commonTop":["Nasopharyngitis","Injection site induration","Injection site erythema","Blood creatine phosphokinase increased","Injection site pain"]}}